What Is Plasma Exchange

Plasma exchange, also called therapeutic plasma exchange or plasmapheresis, is a medical procedure that separates blood plasma from its cellular components, discards the plasma, and returns the blood cells to the patient along with a replacement fluid such as albumin. The procedure physically removes circulating antibodies, inflammatory mediators, toxins, and other soluble factors from the bloodstream. Originally developed for autoimmune and hematological disorders, it is now being studied for its potential to influence biological aging by clearing accumulated harmful plasma proteins.

Aging is accompanied by measurable changes in blood plasma composition. Concentrations of pro-inflammatory cytokines, misfolded proteins, and senescence-associated signaling molecules rise with age, while beneficial factors decline. This altered plasma environment directly influences tissue function: aged plasma impairs stem cell activity, promotes fibrosis, and accelerates organ decline. The observation that these changes are carried in the plasma itself, rather than in cells, opens a therapeutic angle.

Parabiosis experiments in mice, where the circulatory systems of young and old animals are surgically joined, demonstrated that old animals could regain tissue function when exposed to young blood. Subsequent research suggested that the rejuvenating effect may depend less on receiving young factors and more on diluting or removing old ones. Plasma exchange offers a practical, non-surgical way to achieve that dilution in humans, making it a focal point for translational aging research.

During plasma exchange, blood is drawn from a large-bore intravenous line or catheter, typically in the arm or neck. The blood passes through a separation device, either a centrifuge that spins plasma away from denser cells or a membrane filter with pores sized to allow plasma proteins through while retaining blood cells. The separated plasma, along with its dissolved contents, is collected and discarded.

The patient's blood cells are then mixed with a replacement solution, most commonly five percent human albumin, and returned to the body. Albumin replacement restores oncotic pressure (the force that keeps fluid in blood vessels) without reintroducing the problematic proteins that were removed. In some protocols, fresh frozen plasma from donors is used instead, which also replaces clotting factors but carries additional risks including allergic reactions and pathogen transmission.

From a longevity perspective, the mechanism of interest is systemic dilution of the aged secretome. By removing a volume of plasma and replacing it with clean albumin, the procedure reduces the concentration of pro-aging factors such as CCL11 (eotaxin), beta-2-microglobulin, and elevated fibrinogen, while also lowering the burden of autoantibodies and advanced glycation end products. This reset of the plasma environment may temporarily restore more youthful signaling to tissues, improving stem cell function in muscle, brain, and liver. The effects observed in animal models include improved neurogenesis, reduced neuroinflammation, and enhanced muscle repair following neutral blood exchange, a procedure analogous to plasma exchange with albumin.

A plasma exchange session typically begins with placement of one or two large-bore intravenous lines, or a temporary central venous catheter if peripheral access is insufficient. The patient reclines in a treatment chair while the apheresis machine draws blood at a controlled rate, separates the plasma, and returns cells mixed with replacement albumin. Sessions last roughly two to four hours, and patients are monitored for blood pressure, heart rate, and symptoms of citrate reaction throughout.

During the procedure, some patients experience mild tingling around the lips or fingers from calcium shifts caused by the citrate anticoagulant; this is usually managed with oral or intravenous calcium supplementation. Lightheadedness or a sensation of coolness is common as replacement fluid enters the body. Most patients feel fatigued afterward and benefit from resting for the remainder of the day. A series of sessions, often scheduled every other day, is typical for both clinical and investigational protocols.

Pre-procedure labs generally include a complete blood count, comprehensive metabolic panel, coagulation studies, and immunoglobulin levels. These are repeated after the series to track recovery. Patients should expect to avoid strenuous activity for 24 hours after each session and to stay well hydrated.

For established medical indications, plasma exchange is typically performed as a series of five to seven sessions over two to three weeks, with each session exchanging roughly one plasma volume (about three liters in an average adult). Some chronic conditions require maintenance exchanges at longer intervals, such as monthly.

For investigational longevity applications, no standardized protocol exists. The animal research that sparked interest used a single large-volume exchange session. Human protocols being explored at various clinics often involve three to five sessions over one to two weeks, with some practitioners suggesting repeating the series every six to twelve months. The rationale for spacing is to allow immunoglobulin and clotting factor levels to recover fully between series while attempting to maintain a lower burden of pro-aging plasma factors. Without definitive human trial data, these schedules remain empirical.

Therapeutic plasma exchange is a hospital-grade procedure with costs that reflect the equipment, disposables, replacement fluids, and medical supervision involved. When performed for approved medical indications, insurance may cover a significant portion, though copays and facility fees vary. For elective or longevity-oriented use, which is not covered by insurance, patients should expect to pay between $2,000 and $5,000 per session at most U.S. clinics, with a full series of five sessions potentially reaching $10,000 to $25,000. Some longevity clinics bundle the procedure with diagnostics and follow-up labs, which can increase the total cost. Prices outside the United States, particularly in parts of Europe and Asia, may be lower but vary widely depending on facility quality and regulatory environment.

The strongest clinical evidence for plasma exchange comes from its use in autoimmune and hematological conditions, where decades of controlled trials and guidelines from organizations like the American Society for Apheresis support its efficacy for conditions such as Guillain-Barré syndrome, myasthenia gravis, and thrombotic thrombocytopenic purpura. In these settings, the procedure is well characterized in terms of safety and dosing.

The aging and longevity application is far earlier in its evidence trajectory. Mouse studies using neutral blood exchange (replacing half the plasma volume with saline and albumin) have shown improvements in neurogenesis, reduced brain inflammation, restored muscle repair, and improved liver function in aged animals. These results suggest that the benefit of heterochronic parabiosis experiments may come primarily from dilution of old factors rather than transfer of young ones. Human data for aging applications remain sparse: small observational reports and pilot studies exist, but no large randomized controlled trial has tested plasma exchange specifically as a longevity intervention. The duration of any rejuvenating effects, optimal frequency, and long-term safety of repeated elective exchange in otherwise healthy older adults are all open questions.

Plasma exchange carries real procedural risks including hypotension, citrate-induced hypocalcemia (which can cause tingling, cramping, or cardiac arrhythmias), allergic reactions to replacement fluids, and catheter-related infections. Each session depletes clotting factors and immunoglobulins; repeated exchanges without adequate recovery intervals can increase bleeding risk and susceptibility to infections. The procedure is resource-intensive, requiring vascular access, anticoagulation, and medical supervision. When pursued outside of established medical indications, patients should verify that the provider has appropriate training in apheresis medicine and that pre-procedure and post-procedure lab monitoring is part of the protocol.